ADCX 020
Alternative Names: ADCX-020Latest Information Update: 24 Feb 2026
At a glance
- Originator Adcytherix
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Feb 2026 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in Australia (IV) (NCT07238075)
- 20 Nov 2025 Adcytherix SAS plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) (IV) in February 2026 (NCT07238075)
- 16 Oct 2025 Adcytherix announced the intention to submit clinical trial application to European Medicines Agency for Cancer by end of 2025